Author: Mark

  • India’s Private Credit Boom — The Market That’s Redefining Corporate Financing

    India’s Private Credit Boom — The Market That’s Redefining Corporate Financing

    India’s private credit market is scaling faster than any other alternative asset class. Across mid-market and growth-stage companies, demand for non-dilutive, flexible capital is hitting all-time highs. With traditional lenders tightening underwriting standards and equity becoming expensive, private credit has emerged as the strategic middle path.

    Why Private Credit Is Scaling So Fast

    • Credit gaps in banks due to risk caps
    • Equity dilution fatigue among founders
    • Rising capex-intensive industries (manufacturing, EV, healthcare, infra-light tech)
    • Faster turnaround and custom structures vs. vanilla bank term loans

    India’s private credit AUM is expected to cross US$100 billion by 2030, powered by structured debt, revenue-based financing, asset-backed lending, and special situations.

    Where The Capital Is Flowing

    • Manufacturing expansions
    • Working capital + inventory financing
    • Healthcare & pharma capex
    • Renewable energy and green infra
    • Digital-first companies with steady revenue curves

    What’s Changing in 2025–2030

    • More global credit funds are entering India
    • Rise of bespoke structures (bullet, mezzanine, hybrid, DIP financing)
    • Growing acceptance of debt across founder ecosystems
    • Faster adoption among mid-sized corporates

    Private credit is no longer an alternative. It is becoming the backbone of India’s growth story.

  • AI: The New-Age Revolution Reshaping Business, Capital, and the Future of Private Credit

    AI: The New-Age Revolution Reshaping Business, Capital, and the Future of Private Credit


    Introduction-

    Every era has its defining inflexion point.
    The 19th century had the steam engine.
    The 20th century had the internet.
    The 21st century now has Artificial Intelligence — and this shift is already proving larger, faster, and more economically consequential than its predecessors.

    From boardrooms to balance sheets, AI isn’t just another technology wave — it’s becoming the operating system of modern business. And for lenders, investors, and private credit players, it’s quietly rewriting how risk is assessed, how value is measured, and where the next decade’s capital flows will be created.

    AI Is the New Opportunity Engine

    McKinsey’s Superagency report signals what many leaders already feel in real time:

    • $4.4 trillion in annual productivity upside from enterprise AI.
    • 92% of companies plan to increase AI investments in the next 3 years.
    • Only 1% have fully implemented AI across workflows.
    • Employees are using AI 3x more than leadership estimates.
    • 47% of C-suite leaders admit their AI adoption is too slow.

    What Leaders Need to Understand

    AI isn’t a tool upgrade. It’s a capability shift.

    Erik Brynjolfsson puts it sharply:

    “This is a time when you should be getting benefits — and hoping your competitors are only experimenting.”

    Employees already know the shift is happening.
    Leadership, however, is still catching up:

    • C-suite leaders are 2.4x more likely to blame employee readiness than their own alignment.
    • Yet employees use GenAI 3x more than leaders assume.
    • 48% of employees say training is the #1 barrier — not willingness.

    The workforce is ready.
    Leadership needs to catch up — and fund the transformation with intention.

    The Science Is Scaling — And So Is the Economic Impact

    Within two years, AI capabilities have expanded at a pace no industry has ever seen:

    • Google’s Gemini 1.5 grew from 1 million tokens to 2 million in months.
    • Model accuracy, reasoning, and contextual depth have doubled quarter over quarter.
    • Hardware innovation (NVIDIA’s $4T ascent) is now as critical as software innovation.

    Sundar Pichai captured the moment clearly:

    “AI is more profound than fire or electricity.”

    We’re building systems that will outperform top-tier human expertise in more domains, with compounding improvements every 90 days.

    This is no longer automation — it’s augmentation at an institutional scale.

    The Third Order of Work: The Next Human Promotion

    As AI absorbs repetitive and rules-based tasks, human work is entering what researchers call the Third Order of Work:

    1. First Order: Manual tasks
    2. Second Order: Cognitive tasks
    3. Third Order: Compound, creative, strategic, judgment-driven tasks

    This transition will redefine operating models, decision cycles, and value creation.

    For private credit, this shift changes everything — how lenders evaluate companies, how management teams operate, and how risk is priced in a world where human + AI collaboration becomes the new enterprise standard.

    Beyond the Tipping Point

    A look at sentiment across roles reveals a powerful truth:

    • 94% of employees know GenAI tools.
    • 99% of C-suite leaders know them.
    • But leaders believe only 4% of employees use AI for 30% of work — the real number is 3x higher.

    This disconnect is becoming a competitive risk.
    Companies with aligned leadership + AI-literate teams will outpace the market at multiples.

    Millennials (35–44), now the managerial core of corporate India, are emerging as the largest AI-skilled demographic:

    • 62% report high AI proficiency
    • Far more than Gen Z (50%) or baby boomers (22%)

    They will drive enterprise-level AI adoption — if leadership empowers them.

    Trust, Risk, and the New Governance Mandate

    Although employees expect job changes, they trust their employers more than big tech, universities, or startups:

    • 71% trust their company to deploy AI ethically.

    International C-suite leaders are also more aggressive:

    • 55% of Indian executives expect >10% revenue lift from AI
    • Global average: 31%
    • US: 17%

    The winners will be organisations that manage AI responsibly but boldly — balancing governance with innovation.

    Key risks to manage:

    1. Leadership misalignment
    2. Cost inconsistency
    3. Workforce redesign
    4. Supply-chain dependence
    5. Explainability and model risk

    This is not a tech project. It’s a strategic rewiring of the enterprise.

    In some industries, employees are cautious

    · aligning leadership,

    ·      addressing cost uncertainty,

    ·      workforceplanning,

    ·      meeting the demand for explainability.

    What This Means for Private Credit and Corporate Finance

    “Learn from yesterday, live for today, hope for tomorrow”

    -AlbertEinstein, theoretical physicist

    Here’s where the shift becomes extremely relevant for a private credit firm like BMGP:

    1. Business Model Transformation Will Drive Capital Demand

    Companies modernizing with AI will require:

    • Working capital for execution
    • Capex for infrastructure upgrades
    • Debt restructuring for transformation cycles
    • Bridge financing for efficiency-led transitions

    AI adoption = new credit demand cycles.

    2. AI-Enabled Companies Become Lower-Risk Borrowers

    AI-driven enterprises show:

    • Better forecasting accuracy
    • Higher revenue per employee
    • Lower operational risk
    • Faster decision cycles
    • More transparent data trails

    For lenders, this means cleaner underwriting and more confidence in long-term repayment.

    3. Credit Underwriting Itself Is Being Rewritten

    AI enables:

    • Real-time cashflow modelling
    • Sector-specific risk benchmarks
    • Pattern-based borrower screening
    • Dynamic covenant monitoring

    The private credit firms that adopt AI early will underwrite faster, price more accurately, and scale smarter.

    4. New Asset Classes Will Emerge

    Expect rapid growth in:

    • AI transformation financing
    • Data infrastructure credit
    • AI-enabled SaaS revenue financing
    • Digital operations refinancing
    • Cross-border AI expansion debt (India ↔ UAE)

    The firms that recognize this shift early will capture premium yield opportunities.

    The Leadership Requirement: Rewire or Fall Behind

    McKinsey’s Rewired Framework outlines the six pillars leaders must build:

    1. Roadmap
    2. Talent
    3. Operating model
    4. Technology
    5. Data
    6. Scaling

    This is not optional anymore.
    AI is the biggest corporate restructuring driver since globalization — and the companies that delay are already falling behind competitors who are aggressively transforming.


    Conclusion

    Einstein once said:

    “Learn from yesterday, live for today, hope for tomorrow.”

    AI pushes us to do all three.
    Yesterday teaches us that every major technological shift reshapes economic power.
    Today demands bold, strategic adoption.
    Tomorrow belongs to the companies — and lenders — who see AI not as a threat, but as a multiplier.

    For business leaders and private credit players alike, the question is no longer “Is AI important?”
    It’s “How fast can we integrate it into strategy, capital, and execution?”

    The next decade of corporate growth — and private credit opportunity — will be written by the companies that answer that question with conviction.

  • India’s Pharmaceutical  Revolution

    India’s Pharmaceutical Revolution

    India’s pharmaceutical sector has quietly transitioned from being the “world’s generics factory” to becoming one of the most strategic and future-ready life sciences ecosystems globally. Today, the country stands among the top ten most attractive destinations for global pharma investment, exporting to 200+ nations — including the world’s most regulated markets: the US, Western Europe, Japan, and Australia.
    India already commands 20% of the global generics market, and the industry is now targeting ₹11,08,380 crore (US$130 billion) in size by 2030. Biotechnology, running in parallel, is projected to reach ₹25,57,800 crore (US$300 billion) by 2030 and US$450 billion by 2047.

    With 3,000+ pharma companies, ~10,500 manufacturing units, and a globally integrated supply chain, India ranks 3rd worldwide in pharmaceutical production by volume and 14th by value. The sector’s export engine remains strong —
    ₹2,59,658 crore (US$30.38 billion) in FY25 and ₹2,43,119 crore (US$27.82 billion) in FY24.

    India’s domestic pharma market stands at ₹4,70,085 crore (US$55 billion), with exports contributing over US$25 billion. Notably, 1 out of every 5 generic drugs exported globally originates in India, supporting almost 160 crore people — 20% of the world’s population.


    The AI and GenAI Revolution: The Sector’s New Growth Curve

    The biggest structural shift underway is digital.
    Across the pharma value chain, AI adoption is accelerating:

    • 50% of Indian pharma companies are already experimenting with AI
    • 25% have GenAI live in production
    • Resulting in 30–40% productivity gains in sales, supply chain, and manufacturing

    1. Drug Discovery & Development

    • AI-driven molecule prediction
    • Rapid drug repurposing
    • Faster clinical trial design and patient matching
      Impact: Shorter R&D cycles, multi-year cost savings.

    2. Manufacturing & Operations

    • Predictive maintenance
    • Computer-vision-led quality control
    • Process optimisation at scale
      Impact: EY reports 35–40% gains in operational and supply chain efficiency.

    3. Regulatory & Compliance

    • Automated dossier creation
    • AI-assisted documentation for FDA/EMA/CDSCO
      Impact: Faster submissions and accelerated market access.

    4. Sales & Marketing

    • AI-based prescriber segmentation
    • GenAI copilots for medical reps
    • Market demand forecasting
      Impact: 35% uplift in sales productivity.

    5. Supply Chain & Logistics

    • Forecast-based inventory planning
    • Cold-chain monitoring
    • Real-time shipment visibility
      Impact: Lower wastage, higher reliability.

    6. Pharmacovigilance

    • AI-powered adverse event detection
    • Automated case processing
      Impact: Stronger patient safety and regulatory compliance.
    FunctionAdoption MaturityTypical Gains
    Drug DiscoveryHighFaster pipelines, reduced R&D cost
    Manufacturing & OpsHigh30–40% productivity growth
    Sales & MarketingMedium–High35% sales uplift
    RegulatoryMediumFaster submissions
    Supply ChainMediumLower wastage, better visibility
    PharmacovigilanceMediumImproved safety monitoring

    Policy Tailwinds Strengthening the Sector

    The government has reinforced the sector through major initiatives:

    PLI Scheme

    • ₹15,000 crore (US$2.04 billion) from 2020–21 to 2028–29
    • Incentivising API, KSM, and advanced formulations
    • ₹604 crore disbursed in H1 FY25

    Strengthening of Pharmaceutical Industry (SPI)

    • ₹500 crore (US$60.6 million) to support MSME clusters, quality, and sustainability

    Pradhan Mantri Bhartiya Jan Aushadhi Kendras

    • Targeting 10,500 stores by March 2025
    • Offering 1,451 drugs and 240 surgical items at affordable pricing

    India’s Pharma and Biotech: Positioned for Global Dominance

    • One of the top 12 biotech destinations globally
    • 3rd largest biotech hub in Asia-Pacific
    • Bioeconomy valued at US$137 billion (2022); targeting US$300 billion by 2030

    With strong manufacturing depth, scientific talent, regulatory confidence, and a fast-maturing AI ecosystem, India’s pharmaceutical and biotech sectors are entering their most transformative decade.

    This is not just a manufacturing story — it is a strategic, technology-powered healthcare revolution shaping global outcomes.